News

The company has reported a net loss of $12.75m, or $0.17 per share, for the second quarter of fiscal year 2012, compared to net loss of $14.23m, or

These methods are broadly utilized as a part of Precision’s DNE genome engineering technology, the company said. Precision announced in October 2011 that it has asserted the ‘867

The IDMC reviewed all available study data and determined that the trial should continue as designed and conducted, which is the third such review and recommendation by the

The neglected tropical diseases include Chagas disease, helminth infections, leishmaniasis and sleeping sickness. Under the collaboration, DNDi and Abbott scientists will focus initial efforts on discovering and advancing

The VANISH-2 has evaluated the safety and efficacy of Varisolve in patients with symptomatic and visible varicose veins and saphenofemoral junction incompetence. The study met all primary, secondary

AMT has developed Glybera as a treatment for patients with the genetic disorder lipoprotein lipase deficiency (LPLD). On 23 October 2011, AMT received a non-approvable opinion from the

The NDA was withdrawn as the company required additional time to prepare for the review of the Pixuvri NDA by the FDA’s Oncologic Drugs Advisory Committee (ODAC). CTI

Under the terms of the distribution agreement, Alphamed will sell Arabio’s human vaccines and drugs in the UAE market. Arabio general manager Majed Bahatheq said that Arabio is

The assay is a molecular diagnostic assay that differentiates between patients at high, intermediate or low risk of early death after surgery to remove a non-squamous, non-small cell